In preclinical studies, CFZ has shown single-agent activity against hematopoietic malignancies and some solid tumors, such as head and neck cancer, through inhibiting NF-κB activation by preventing ubiquitination and proteasome degradation of IκBα as well as through other NF-κB related biological mechanisms (22–25). The gene discussed is NFKB1; the disease is head and neck cancer.